Synthetic Cannabinoids Influence the Invasion of Glioblastoma Cell Lines in a Cell- and Receptor-Dependent Manner. 2019

Tim Hohmann, and Kerstin Feese, and Thomas Greither, and Chalid Ghadban, and Vivian Jäger, and Faramarz Dehghani, and Urszula Grabiec
Institute of Anatomy and Cell Biology, Medical Faculty of Martin Luther University Halle-Wittenberg, Grosse Steinstrasse 52, 06108 Halle (Saale), Germany. tim.hohmann@medizin.uni-halle.de.

The current treatment of glioblastoma is not sufficient, since they are heterogeneous and often resistant to chemotherapy. Earlier studies demonstrated effects of specific cannabinoid receptor (CB) agonists on the invasiveness of glioblastoma cell lines, but the exact mechanism remained unclear. Three human glioblastoma cell lines were treated with synthetic CB ligands. The effect of cannabinoids on microRNAs (miRs), Akt, and on the expression of proliferation and apoptosis markers were analyzed. Furthermore, in a model of organotypic hippocampal slice cultures cannabinoid mediated changes in the invasiveness were assessed. MicroRNAs and the activation of Akt which are related to cell migration, apoptosis, and proliferation were evaluated and found not to be associated with changes in the invasiveness after treatment with CB ligands. Also proliferation and/or apoptosis were not altered after treatment. The effects of cannabinoids on invasiveness could be blocked by the application of receptor antagonists and are likely mediated via CB₁/CB₂. In conclusion, our results suggest that cannabinoids can influence glioblastoma cell invasion in a receptor and cell type specific manner that is independent of proliferation and apoptosis. Thus, cannabinoids can potentially be used in the future as an addition to current therapy.

UI MeSH Term Description Entries

Related Publications

Tim Hohmann, and Kerstin Feese, and Thomas Greither, and Chalid Ghadban, and Vivian Jäger, and Faramarz Dehghani, and Urszula Grabiec
December 2003, British journal of cancer,
Tim Hohmann, and Kerstin Feese, and Thomas Greither, and Chalid Ghadban, and Vivian Jäger, and Faramarz Dehghani, and Urszula Grabiec
October 2013, Investigational new drugs,
Tim Hohmann, and Kerstin Feese, and Thomas Greither, and Chalid Ghadban, and Vivian Jäger, and Faramarz Dehghani, and Urszula Grabiec
August 2013, EMBO reports,
Tim Hohmann, and Kerstin Feese, and Thomas Greither, and Chalid Ghadban, and Vivian Jäger, and Faramarz Dehghani, and Urszula Grabiec
June 2004, The Journal of pharmacology and experimental therapeutics,
Tim Hohmann, and Kerstin Feese, and Thomas Greither, and Chalid Ghadban, and Vivian Jäger, and Faramarz Dehghani, and Urszula Grabiec
October 2012, Molecular cancer research : MCR,
Tim Hohmann, and Kerstin Feese, and Thomas Greither, and Chalid Ghadban, and Vivian Jäger, and Faramarz Dehghani, and Urszula Grabiec
May 2021, Pharmacology research & perspectives,
Tim Hohmann, and Kerstin Feese, and Thomas Greither, and Chalid Ghadban, and Vivian Jäger, and Faramarz Dehghani, and Urszula Grabiec
January 2020, OncoTargets and therapy,
Tim Hohmann, and Kerstin Feese, and Thomas Greither, and Chalid Ghadban, and Vivian Jäger, and Faramarz Dehghani, and Urszula Grabiec
September 2012, Experimental cell research,
Tim Hohmann, and Kerstin Feese, and Thomas Greither, and Chalid Ghadban, and Vivian Jäger, and Faramarz Dehghani, and Urszula Grabiec
January 2019, Cancer cell international,
Tim Hohmann, and Kerstin Feese, and Thomas Greither, and Chalid Ghadban, and Vivian Jäger, and Faramarz Dehghani, and Urszula Grabiec
April 2017, Oncotarget,
Copied contents to your clipboard!